SCHEMBL4748504

SCHEMBL4748504

O=[N+]([O-])c1ccc2c(c1)ncn2Cc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.77
NR1I2 O75469 6/20 0.69
ALDH1A1 P00352 3/20 0.61
BRD4 O60885 1/20 0.58
KCNH2 Q12809 1/20 0.58
TNF P01375 1/20 0.57
CYP11B1 P15538 1/20 0.57
CYP11B2 P19099 1/20 0.57
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
CYP2C9 P11712 1/20 0.53
HPGD P15428 1/20 0.53
CYP2C19 P33261 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
FGFR1 P11362 1/20 0.51
CNR1 P21554 1/20 0.51
ACHE P22303 1/20 0.51
CNR2 P34972 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8593796 0.90 PKM (0.64) PKMNR1I2ALDH1A1BRD4KCNH2
SCHEMBL8593799 0.90 PKM (0.64) PKMNR1I2ALDH1A1BRD4KCNH2
SCHEMBL7029418 0.89 PKM (0.62) PKMNR1I2ALDH1A1BRD4TNF
SCHEMBL2841823 0.87 PKM (1.00) PKMNR1I2ALDH1A1BRD4KCNH2
SCHEMBL30229258 0.87 PKM (0.62) PKMNR1I2ALDH1A1BRD4KCNH2
SCHEMBL3055818 0.84 PKM (0.69) PKMNR1I2ALDH1A1BRD4KCNH2
SCHEMBL2023928 0.83 CYP11B1 (0.65) PKMNR1I2ALDH1A1TNFCYP11B1
SCHEMBL19911377 0.83 PKM (0.64) PKMNR1I2ALDH1A1BRD4KCNH2
SCHEMBL2028857 0.83 CYP11B1 (0.61) PKMNR1I2ALDH1A1TNFCYP11B1
SCHEMBL11797084 0.80 PKM (0.64) PKMNR1I2ALDH1A1BRD4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
WO-2015171951-A1 2-(4-ARYL-1H-IMIDAZOL-1-YL)ANILINE COMPOUNDS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2015-11-12 WO disclosed
WO-2008134354-A1 TNF-α PRODUCTION INHIBITOR ARRAY BIOPHARMA, INC. (US) 2008-11-06 WO disclosed
EP-0843671-A1 HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 1998-05-27 EP disclosed
WO-1997003069-A1 HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 1997-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 PKM 2292/4885NR1I2 3519/4885ALDH1A1 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.